Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka Replagal

Agalsidase alfa — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Agalsidase alfa (also known as Replagal) is a peptide catalogued under Enzymes (Fabry). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Agalsidase alfa?

Agalsidase alfa (brand name Replagal) is a recombinant human alpha-galactosidase A used as enzyme replacement therapy for Fabry disease, an X-linked lysosomal storage disorder caused by deficient alpha-Gal A and accumulation of globotriaosylceramide (Gb3).

It is approved by the European Medicines Agency and marketed in many countries, but it is NOT approved by the US FDA; in the United States the alternative agalsidase beta (Fabrazyme) is used instead.

Evidence comes from human randomized controlled trials and long-term observational cohorts, so this is an established, regulator-approved therapy rather than an experimental compound.

How does Agalsidase alfa work?

Agalsidase alfa supplies a functional copy of the deficient lysosomal enzyme alpha-galactosidase A, which is taken up by cells via mannose-6-phosphate receptors and hydrolyzes accumulated globotriaosylceramide (Gb3) in lysosomes.

Because the intravenous enzyme does not cross the blood-brain barrier, it clears substrate in peripheral tissues (kidney, heart, vasculature) but is not expected to reverse central nervous system manifestations.

What does the research say about Agalsidase alfa?

  • In a randomized controlled trial, agalsidase alfa reduced neuropathic pain and stabilized renal function versus placebo in men with Fabry disease. [1]
  • A randomized, double-blind, placebo-controlled trial showed agalsidase alfa reduced left ventricular mass, improving the cardiomyopathy of Fabry disease. [2]
  • At a matched 0.2 mg/kg dose, agalsidase alfa produced biochemical and clinical outcomes comparable to agalsidase beta in a head-to-head comparative trial. [3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Enzyme replacement therapy in Fabry disease: a randomized controlled trial — Schiffmann R et al., JAMA 2001. (Randomized controlled trial)
  • [2] Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa — Hughes DA et al., Heart 2008. (Randomized double-blind placebo-controlled trial)
  • [3] Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg — Vedder AC et al., PLoS One 2007. (Randomized comparative trial)
  • [4] Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing — Schiffmann R et al., Journal of the American Society of Nephrology 2007. (Open-label interventional study)
  • [5] A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease — Schiffmann R et al., Journal of Inherited Metabolic Disease 2015. (Prospective long-term cohort)
  • [6] Agalsidase alfa: a review of its use in the management of Fabry disease — Keating GM et al., BioDrugs 2012. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In published trials the studied regimen is 0.2 mg/kg given by intravenous infusion once every two weeks, a lower per-dose amount than the 1.0 mg/kg every two weeks used for agalsidase beta.

This is provided as background on how the drug has been studied and is not dosing guidance; Fabry disease ERT must be prescribed and monitored by a specialist metabolic team.

Side effects & safety profile

The most common adverse events are infusion-related reactions (chills, fever, flushing, headache), which are usually mild-to-moderate and manageable with slowing the infusion or premedication.

Some patients, particularly males with little residual enzyme, develop anti-drug (IgG) antibodies whose long-term clinical impact remains uncertain.

Because the enzyme does not cross the blood-brain barrier, it is not expected to treat the neurological or cerebrovascular features of Fabry disease.

Stacking & combinations

This is a physician-administered rare-disease biologic, not a compound used in combination or stacking regimens; adjunctive care focuses on supportive treatment (for example pain, renal, and cardiac management).

Finding Agalsidase alfa vendors

Finding Agalsidase alfa vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

It is an enzyme replacement therapy for Fabry disease, replacing the deficient enzyme alpha-galactosidase A to clear accumulated Gb3 from tissues.

References

  1. [1] Enzyme replacement therapy in Fabry disease: a randomized controlled trial — Schiffmann R et al., JAMA 2001. PMID: 11386930. View sourceStudy: Randomized controlled trialAgalsidase alfa reduced neuropathic pain and helped stabilize renal function versus placebo.
  2. [2] Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa — Hughes DA et al., Heart 2008. PMID: 17483124. View sourceStudy: Randomized double-blind placebo-controlled trialAgalsidase alfa significantly reduced left ventricular mass compared with placebo.
  3. [3] Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg — Vedder AC et al., PLoS One 2007. PMID: 17622343. View sourceStudy: Randomized comparative trialAt an equal 0.2 mg/kg dose the two agalsidase products gave comparable biochemical and clinical outcomes.
  4. [4] Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing — Schiffmann R et al., Journal of the American Society of Nephrology 2007. PMID: 17409308. View sourceStudy: Open-label interventional studyIncreasing to weekly dosing was associated with slower decline of renal function in some patients.
  5. [5] A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease — Schiffmann R et al., Journal of Inherited Metabolic Disease 2015. PMID: 25900714. View sourceStudy: Prospective long-term cohortIndividualized intensified agalsidase alfa was associated with relative stabilization of renal function over 10 years in advanced disease.
  6. [6] Agalsidase alfa: a review of its use in the management of Fabry disease — Keating GM et al., BioDrugs 2012. PMID: 22946754. View sourceStudy: Narrative reviewReviews evidence that agalsidase alfa improves cardiac, renal, pain and quality-of-life outcomes with a generally acceptable tolerability profile.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.